Tenon Medical, Inc.
NNASDAQ:TNONCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Steven M. Foster
- Full Time Employees
- 26
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- 104 Cooper Court Los Gatos CA United States 95032
- IPO Date
- Apr 27, 2022
- CIK
- 0001560293
- Website
- tenonmed.com
- Similar Companies
- Business
- Tenon Medical, Inc. is a medical device company specializing in sacroiliac (SI) joint fusion solutions primarily aimed at patients suffering from sacro-pelvic disorders and chronic SI joint pain. Founded in 2012 and headquartered in Los Gatos, California, Tenon Medical manufactures and sells the Catamaran SI Joint Fusion System, a minimally invasive surgical implant system that uses a single robust titanium implant for stabilizing the SI joint. The company's product portfolio has expanded to include the SImmetry+ SI Joint Fusion System, a next-generation, minimally invasive lateral-access system featuring 3D-printed titanium implants designed for joint decortication, bone graft delivery, and fixation to achieve biological fusion across the SI joint. Tenon targets multiple commercial opportunities including primary SI joint procedures, revision surgeries for failed implants, and SI joint fusion adjuncts for spinal fusion surgeries. In the last two years, Tenon Medical has undergone significant strategic transformations. The company completed a $2.85 million at-the-market PIPE financing in November 2025 to support working capital and growth initiatives. In 2025, Tenon acquired CyVantage, which transformed it into a multi-product leader in SI joint fusion, diversifying its revenue streams and expanding its market reach by integrating the Symmetry product line and launching the new Symmetry+ system in late 2025. This multi-platform, multi-approach strategy strengthens Tenon's competitive position in the expanding SI joint fusion market. The company has also focused on reducing operating expenses by 29% year-over-year while maintaining strong financial health with $7.8 million in cash and no outstanding debt as of mid-2025. The SImmetry+ system has gained FDA 510(k) clearance and is undergoing a controlled early access rollout with select surgeons, reinforcing Tenon's commitment to innovative, clinically supported sacro-pelvic surgical solutions. Tenon Medical operates primarily in the medical device industry within the spine and orthopedic segments, catering to hospitals, surgical centers, and spine specialists across the United States and expanding internationally. The company is driven by clinical evidence-based product development and aims to provide durable, reliable fusion outcomes with its implant systems tailored to patient anatomy and pathology. Tenon's integrated product offerings now include Catamaran and SImmetry platforms, which provide surgeons with multiple options for SI joint stabilization in primary, revision, and adjunctive spinal fusion procedures, positioning Tenon as a growing force in the sacro-pelvic fusion market. This growth is underpinned by a highly experienced management team and a commercial infrastructure capable of supporting broad market adoption and new product launches.
Company News
Tenon Medical(R) Adds Eight New Patents Issued by the United States Patent and Trademark Office Through Q3 2026
Tenon Medical, Inc. (NASDAQ:TNON) Sees Large Drop in Short Interest
Tenon(R) Medical Announces Full Commercial Launch of the SImmetry(R)+ SI Joint Fusion 3D Printed Lateral Screw Following Successful Alpha Launch
WallachBeth Capital Announces Closing of Tenon Medical Warrant Inducement Offering for Aggregate Gross Proceeds of Approximately $2,872,338
Tenon Medical Announces Closing of Warrant Inducement Offering for Aggregate Gross Proceeds of Approximately $2,872,338
WallachBeth Capital Announces Tenon Medical Warrant Inducement for Gross Proceeds of Approximately $2,872,338
Tenon Medical Announces Warrant Inducement for Aggregate Gross Proceeds of Approximately $2,872,338
Tenon Medical Stock Extends Multi-Day Rally: What's Happening?
Tenon Medical Announces Early Repayment of Its Convertible Notes
/C O R R E C T I O N -- WallachBeth Capital LLC/
WallachBeth Capital Announces Closing of Tenon Medical
WallachBeth Capital Announces Closing of Tenon Medical
Tenon Medical Announces Closing of $3M Private Placement Offering
Tenon Medical Stock Climbs Friday: What's Going On?
WallachBeth Capital Announces Tenon Medical Pricing of $3M Private Placement Offering
Tenon Medical Announces Pricing of $3M Private Placement Offering
Tenon Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement
Tenon Medical, Inc. (TNON) Q2 2026 Earnings Call Transcript
Tenon Medical Reports Second Quarter 2026 Financial Results
Tenon Medical, Inc. Announces 1:35 Reverse Stock Split